Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting

Phase 1

Phase 2

TuspetinibClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Sponsor:

Aptose Biosciences Inc.

Code:

NCT03850574

Conditions

Leukemia, Myeloid, Acute

Refractory AML

Relapsed Adult AML

Myelodysplastic Syndrome With Excess Blasts-2

Chronic Myelomonocytic Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tuspetinib

Venetoclax Oral Tablet

Azacitidine for Intravenous Infusion

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-27. This information was provided to ClinicalTrials.gov by Aptose Biosciences Inc. on 2025-08-26.